Axa S.A. Alnylam Pharmaceuticals, Inc. Transaction History
Axa S.A.
- $32.2 Billion
- Q4 2024
A detailed history of Axa S.A. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Axa S.A. holds 95,306 shares of ALNY stock, worth $25.7 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
95,306
Previous 111,216
14.31%
Holding current value
$25.7 Million
Previous $30.6 Million
26.7%
% of portfolio
0.07%
Previous 0.09%
Shares
35 transactions
Others Institutions Holding ALNY
# of Institutions
671Shares Held
108MCall Options Held
839KPut Options Held
771K-
Capital World Investors Los Angeles, CA16.6MShares$4.48 Billion0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$3.44 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.58 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.97MShares$1.88 Billion0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.38MShares$1.18 Billion0.64% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $33.2B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...